Navigation Links
Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Date:9/25/2008

c disorders to the Company, but also a strong background in strategy, medical affairs and management."

The Senior Vice President and Head of Obesity and Metabolic Disorders is a new position at Orexigen. Dr. Kim will report to Eduardo Dunayevich, M.D., Chief Medical Officer.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 VetStem Biopharma, proudly announces ... Jeffrey Schaffer, DVM, as Director of Veterinary Professional ... of experience in the veterinary regenerative medicine field ... our veterinarian lead organization”. Dr. Alexis Nahama, ... will be responsible for all technical activities in ...
(Date:5/5/2015)... , May 5, 2015 Psyche Systems ... alliance which offers a first-of-its-kind platform that helps labs ... to lab results, transforms the way patients engage with ... Luminate Health provides a HIPAA-compliant digital platform ... access, manage, and understand their lab results, and uniquely ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... Corporation,s (NYSE AMEX LLC: ETC) ("ETC" or the ... of Mr. Ray Wyngarden as Western Regional Sales ... expanding market awareness of the BARA-MED(R) XD Monoplace ... the western portion of the United States.Mr. Wyngarden,s ...
... Group at Frost & Sullivan is ... Presentation on the Global Active Pharmaceutical Ingredients (API) ... 2009, at 3 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )The ... is currently witnessing a rapid shift towards biopharmaceuticals. ...
... Traditional Cardiac Safety Approaches , ... ... a leading innovator in advanced cardiac safety biomarkers and automated ... of pharmaceutical companies, biotechnology companies and industry consultants. When ...
Cached Biology Technology:Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics 2The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics 3Avoiding False Positives Key Priority in Cardiac Safety Studies 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... is present when it comes to human evolution. ... that concludes "archaic" humans, somewhere in Africa during the ... and transferred small amounts of genetic material to their ... geneticist Michael Hammer and a team of evolutionary biologists, ...
... from custom DNA molecules could be used to personalize cancer ... an international team of researchers led by scientists at UC ... The new nanosensors can quickly detect a broad class of ... switches of life. The research is described in an article ...
... New research from the Keck School of Medicine of ... damage to the liver caused by drugs like acetaminophen ... Tylenol, helps relieve pain and reduce fever. The over-the-counter ... flu remedies as well as prescription painkillers like Percocet ...
Cached Biology News:Evolution's past is modern human's present 2Evolution's past is modern human's present 3Nanosensors made from DNA may light path to new cancer tests and drugs 2Nanosensors made from DNA may light path to new cancer tests and drugs 3USC scientists identify key protein linked to acute liver failure 2
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... offers SNP loci identification through targeting ... assay design, intensive assay validation/optimization, high ... Corriell or customer-supplied samples and sequence ... provides for rapid and highly accurate ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
... These 384-Well Microarray plates are ideal for use ... volume liquid handling applications (down to 5µl). These ... cylindrical well design. Features ... formats available 70µl well volume (cylindrical well), ...
Biology Products: